FI64801C - Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin - Google Patents

Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin Download PDF

Info

Publication number
FI64801C
FI64801C FI791084A FI791084A FI64801C FI 64801 C FI64801 C FI 64801C FI 791084 A FI791084 A FI 791084A FI 791084 A FI791084 A FI 791084A FI 64801 C FI64801 C FI 64801C
Authority
FI
Finland
Prior art keywords
group
formula
parts
benzimidazol
compounds
Prior art date
Application number
FI791084A
Other languages
English (en)
Finnish (fi)
Other versions
FI64801B (fi
FI791084A (fi
Inventor
Frans Janssens
Raymond Stokbroekx
Joseph Torremans
Marcel Luyckx
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26670178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI64801(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/002,276 external-priority patent/US4219559A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of FI791084A publication Critical patent/FI791084A/fi
Publication of FI64801B publication Critical patent/FI64801B/fi
Application granted granted Critical
Publication of FI64801C publication Critical patent/FI64801C/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
FI791084A 1978-04-03 1979-04-02 Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin FI64801C (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89253478A 1978-04-03 1978-04-03
US89253478 1978-04-03
US06/002,276 US4219559A (en) 1979-01-10 1979-01-10 N-Heterocyclyl-4-piperidinamines
US227679 1979-01-10

Publications (3)

Publication Number Publication Date
FI791084A FI791084A (fi) 1979-10-04
FI64801B FI64801B (fi) 1983-09-30
FI64801C true FI64801C (fi) 1984-01-10

Family

ID=26670178

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791084A FI64801C (fi) 1978-04-03 1979-04-02 Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin

Country Status (29)

Country Link
EP (1) EP0005318B1 (fr)
JP (2) JPS54151982A (fr)
AT (1) AT373887B (fr)
AU (1) AU523352B2 (fr)
BG (1) BG38164A3 (fr)
CA (1) CA1140119A (fr)
CS (1) CS256358B2 (fr)
CY (1) CY1250A (fr)
DE (1) DE2961740D1 (fr)
DK (1) DK169325B1 (fr)
EG (1) EG13913A (fr)
ES (1) ES479206A1 (fr)
FI (1) FI64801C (fr)
GR (1) GR64907B (fr)
HK (1) HK3184A (fr)
HU (1) HU182965B (fr)
IE (1) IE47818B1 (fr)
IL (1) IL56992A (fr)
MY (1) MY8500046A (fr)
NO (2) NO154058C (fr)
NZ (1) NZ189978A (fr)
PH (1) PH15877A (fr)
PL (1) PL123380B1 (fr)
PT (1) PT69429A (fr)
RO (1) RO79320A (fr)
SG (1) SG29883G (fr)
SU (1) SU1056902A3 (fr)
YU (2) YU42484B (fr)
ZA (1) ZA791557B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA19091A1 (fr) * 1980-03-10 1981-10-01 Janssen Pharmaceutica Nv Nouveaux derives de i-(4-aryl-cyclohexyl)piperidine .
US4556660A (en) * 1982-07-12 1985-12-03 Janssen Pharmaceutica N.V. N-(Bicyclic heterocyclyl)-4-piperidinamines
IN156065B (fr) * 1982-07-12 1985-05-04 Janssen Pharmaceutica Nv
US4634704A (en) * 1983-10-06 1987-01-06 Janssen Pharmaceutica, N.V. Anti-allergic five membered heterocyclic ring containing N-(bicyclic heterocycyl)-4-piperidinamines
DE3484096D1 (de) * 1983-11-30 1991-03-14 Janssen Pharmaceutica Nv Bizyklisches heterozyklyl aufveisende n-(bizyklisches heterozyklyl-4-piperidinamine.
PL144514B1 (en) * 1984-01-09 1988-06-30 Janssen Pharmaceutica Nv Method of obtaining novel derivatives of n-/4-piperidinolo/-2-imidazoloamine
KR930005004B1 (ko) * 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
EG17993A (en) * 1986-02-03 1991-08-30 Janssen Pharmaceutica Nv Anti-histaminic compositions containing n-heterocyclyl-4-piperidinanines
NZ223654A (en) * 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
FR2618435B1 (fr) * 1987-07-23 1989-10-27 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US5210091A (en) * 1991-06-24 1993-05-11 Neurosearch A/S Imidazole compounds and their use
CA2161876A1 (fr) * 1993-05-20 1994-12-08 Den-Ichi Momose Composes de type 1-(2-benzimidazolyl)-1,5-diazacyclooctane
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
KR20010032968A (ko) * 1998-03-06 2001-04-25 디르크 반테 글리신 수송 저해제
BR0011997A (pt) 1999-06-28 2002-03-05 Janssen Pharmaceutica Nv Inibidores da replicação do vìrus sincicial respiratório
AU778218B2 (en) 1999-06-28 2004-11-25 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
EE04590B1 (et) * 1999-06-28 2006-02-15 Janssen Pharmaceutica N.V. Respiratoorse süntsütiaalviiruse replikatsiooni inhibiitorid, nende kasutamine ja valmistamismeetod, farmatseutiline kompositsioon ja selle valmistamismeetod ning produkt
RU2398765C1 (ru) 2000-03-06 2010-09-10 Акадиа Фармасьютикалз, Инк. Азациклические соединения для применения при лечении опосредованных серотонином заболеваний
CN1876647A (zh) 2001-02-02 2006-12-13 特瓦制药工业有限公司 苯并咪唑化合物产品
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
WO2004000808A2 (fr) 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. Derives de piperidine substitues en n en tant qu'agents recepteurs de la serotonine
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
ES2314362T3 (es) 2003-01-16 2009-03-16 Acadia Pharmaceuticals Inc. Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas.
DK1697347T3 (da) 2003-12-18 2011-06-06 Tibotec Pharm Ltd 5- eller 6-substituerede benzimidazolderivater som inhibitorer af replikation af respiratorisk syncytial-virus
AR046971A1 (es) 2003-12-18 2006-01-04 Tibotec Pharm Ltd Aminobenzoimidazoles y benzoimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
US7355051B2 (en) * 2003-12-18 2008-04-08 Tibotec Pharmaceuticals Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP5154227B2 (ja) 2004-09-27 2013-02-27 アカディア ファーマシューティカルズ インコーポレイテッド N−(4−フルオロベンジル)−n−(1−メチルピペリジン−4−イル)−n’−(4−(2−メチルプロピルオキシ)フェニルメチル)カルバミドの塩及びその調製
JP2010522198A (ja) 2007-03-19 2010-07-01 アカドイア プハルマセウチカルス インコーポレーテッド 5−ht2aインバースアゴニスト及びアンタゴニストの抗精神病薬との併用
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
EP3558311A1 (fr) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
WO2018200977A1 (fr) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
EP3675827A1 (fr) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations de pimavansérine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2857391A (en) * 1955-04-15 1958-10-21 Merck & Co Inc Aminomethylbenzimidazoles
US2971005A (en) * 1958-10-17 1961-02-07 Merck & Co Inc Nu-substituted derivatives of 2-benzylaminobenzimidazoles
BE788065A (fr) * 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation

Also Published As

Publication number Publication date
ATA242579A (de) 1983-07-15
FI64801B (fi) 1983-09-30
FI791084A (fi) 1979-10-04
PL214648A1 (fr) 1980-03-24
AU523352B2 (en) 1982-07-22
YU78479A (en) 1983-10-31
HK3184A (en) 1984-01-20
YU42484B (en) 1988-10-31
BG38164A3 (en) 1985-10-15
DE2961740D1 (en) 1982-02-25
EP0005318A1 (fr) 1979-11-14
DK129879A (da) 1979-10-04
PH15877A (en) 1983-04-13
JPS54151982A (en) 1979-11-29
EG13913A (en) 1982-09-30
NZ189978A (en) 1984-05-31
NO154090B (no) 1986-04-07
IL56992A0 (en) 1979-07-25
CY1250A (en) 1984-08-31
NO154090C (no) 1986-07-16
MY8500046A (en) 1985-12-31
JPH0240666B2 (fr) 1990-09-12
GR64907B (en) 1980-06-07
IL56992A (en) 1983-03-31
JPH01117880A (ja) 1989-05-10
NO842563L (no) 1979-10-04
SU1056902A3 (ru) 1983-11-23
CA1140119A (fr) 1983-01-25
HU182965B (en) 1984-03-28
SG29883G (en) 1984-04-19
NO154058B (no) 1986-04-01
NO791097L (no) 1979-10-04
AT373887B (de) 1984-02-27
YU43158B (en) 1989-04-30
ZA791557B (en) 1980-11-26
PT69429A (pt) 1979-05-01
AU4529679A (en) 1979-10-18
DK169325B1 (da) 1994-10-10
IE790676L (en) 1979-10-03
YU50283A (en) 1983-12-31
ES479206A1 (es) 1979-12-16
CS222779A2 (en) 1987-03-12
CS256358B2 (en) 1988-04-15
PL123380B1 (en) 1982-10-30
NO154058C (no) 1986-07-09
IE47818B1 (en) 1984-06-27
RO79320A (fr) 1982-08-17
EP0005318B1 (fr) 1982-01-06
JPS641477B2 (fr) 1989-01-11

Similar Documents

Publication Publication Date Title
FI64801C (fi) Foerfarande foer framstaellning av n-heterocyklyl-4-piperidinaminer med verkan av antihistamin
US4219559A (en) N-Heterocyclyl-4-piperidinamines
FI81797C (fi) Foerfarande foer framstaellning av en fem-ledad heterocyklisk ring innehaollande terapeutiskt aktiva n-(bicyklisk heterocyklyl)-4-piperidinaminer.
FI83781B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara bicykliska kondenserade n-(4-piperidinyl)-2 -imidazolaminderivat.
FI78480C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara n-(bicyklis heterocyklyl)-4-piperidinaminderivat.
FI82046C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara bensoxazol-, bensotiazol- och tiazolopyridinaminer.
FI93728B (fi) Menetelmä terapeuttisesti käyttökelpoisten etoksietyyli-bentsimidatsoli- tai imidatsopyridiiniyhdisteiden valmistamiseksi
AU730369B2 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
EP1848696A1 (fr) Derives d'imidazole et de benzimidazole utiles en tant qu'antagonistes de l'histamine h3
CA2741661A1 (fr) Nouveau derive amide et son utilisation comme medicament
Janssens et al. New antihistaminic N-heterocyclic 4-piperidinamines. 2. Synthesis and antihistaminic activity of 1-[(4-fluorophenyl) methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amines
FI62667B (fi) Foerfarande foer framstaellning av antiemetiska 1-(benzazolylalkyl)piperidinderivat
CA2600507C (fr) 1,3-dihydrobenzimidazol-2-ylideneamines servant d'inhibiteurs de la replication du virus respiratoire syncytial
FI90233B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten furanyylimetyylisubstituoitujen bentsimidatsoli- ja imidatsopyridiinijohdannaisten valmistamiseksi
CZ183699A3 (cs) 2-Imidazolinylaminobenzoxazolové sloučeniny užitečné jako alfa-2 adrenoceptorové agonisty
JPH01228986A (ja) [(5(6)(1h―アゾール―1―イルメチル)ベンズイミダゾール]カーバメート
RU2188822C2 (ru) Производное бензимидазола и средство, обладающее антагонистической активностью против вещества р и антигистаминовой активностью
DK171841B1 (da) N-hetero-cyclyl-4-piperidinaminer
JPH0413666A (ja) 1―(アルコキシフェニル)―3―(4,5,6,7―テトラヒドロベンズイミダゾリル)ウレア
KR810001715B1 (ko) 5-[4-(디아릴메틸)-1-피페라지닐알킬〕벤즈이미다졸 유도체의 제조방법
Jha Department of Chemistry, Acadia University, Wolfville, B4P 2R6, Nova Scotia, Canada E-mail: amitabh. jha@ acadiau. ca
FI84070B (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara imidazopyridinylaminopiperidinderivat och mellanprodukter anvaendbara i foerfarandet.

Legal Events

Date Code Title Description
MA Patent expired
MA Patent expired

Owner name: JANSSEN PHARMACEUTICA N.V.